| Dee Anne Louise Griffin, FNP-C | |
|
608 E Columbia Ave, Leesville, SC 29070-7318 | |
| (803) 532-0051 | |
| Not Available |
| Full Name | Dee Anne Louise Griffin |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 608 E Columbia Ave, Leesville, South Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518465210 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 21617 (South Carolina) | Primary |
| Entity Name | Dynamic Health Solutions, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972223725 PECOS PAC ID: 7113393042 Enrollment ID: O20221018003059 |
News Archive
Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.
The top attorney for the state of Florida asked a federal appeals court today to reinstate a Florida law that regulates what physicians can ask patients about gun ownership, asserting that the law does not actually stifle such questions. Yes, it does, countered a lawyer representing several Florida medical societies and individual physicians who challenged the law as an infringement on their First Amendment right to free speech (Lowes, 7/18).
New guidelines developed by the American Academy of Neurology find a combination of blood tests and other specialized assessments appear to be the most helpful tests for finding the cause of neuropathy.
A brief report in the February 28, 2008, New England Journal of Medicine, led by researchers at the New England Newborn Screening Program (NENSP) of the University of Massachusetts Medical School (UMMS), indicates a declining incidence of a genetic disease, providing what may be the first demonstration of a link between two independent population-based screening programs.
Chelsea Therapeutics International, Ltd. announced that preliminary analyses of its Phase III NORTHERA™ Study 301 met its primary endpoint. Treatment with Northera provided clinically meaningful and statistically significant improvement.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dee Anne Louise Griffin, FNP-C 51 Saint Albans Rd, Irmo, SC 29063-2558 Ph: (803) 318-9920 | Dee Anne Louise Griffin, FNP-C 608 E Columbia Ave, Leesville, SC 29070-7318 Ph: (803) 532-0051 |
News Archive
Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.
The top attorney for the state of Florida asked a federal appeals court today to reinstate a Florida law that regulates what physicians can ask patients about gun ownership, asserting that the law does not actually stifle such questions. Yes, it does, countered a lawyer representing several Florida medical societies and individual physicians who challenged the law as an infringement on their First Amendment right to free speech (Lowes, 7/18).
New guidelines developed by the American Academy of Neurology find a combination of blood tests and other specialized assessments appear to be the most helpful tests for finding the cause of neuropathy.
A brief report in the February 28, 2008, New England Journal of Medicine, led by researchers at the New England Newborn Screening Program (NENSP) of the University of Massachusetts Medical School (UMMS), indicates a declining incidence of a genetic disease, providing what may be the first demonstration of a link between two independent population-based screening programs.
Chelsea Therapeutics International, Ltd. announced that preliminary analyses of its Phase III NORTHERA™ Study 301 met its primary endpoint. Treatment with Northera provided clinically meaningful and statistically significant improvement.
› Verified 9 days ago
Christy Clemenz Dunbar, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 608 East Columbia Ave, Leesville, SC 29070 Phone: 803-532-8155 Fax: 803-532-9685 | |
Lindsey Busbee White, MSN, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 186 Saluda Waters Rd, Leesville, SC 29070 Phone: 803-507-0451 | |
Victoria Wright Hyatt, CPNP-PC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 141 E Church St, Leesville, SC 29070 Phone: 803-520-9261 | |
Beth Sanders, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 338 E Columbia Ave, Leesville, SC 29070 Phone: 803-532-1580 |